perhexiline has been researched along with Cardiomyopathy, Congestive in 5 studies
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine whether short-term treatment with perhexiline improves cardiac energetics, left ventricular function, and symptoms of heart failure by altering cardiac substrate utilization." | 9.20 | Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. ( Abozguia, K; Beadle, RM; Bowater, S; Frenneaux, MP; Horowitz, J; Kuehl, M; Leyva, F; Thies, F; Wagenmakers, AJ; Williams, LK; Yousef, Z, 2015) |
| "The aim of this study was to determine whether short-term treatment with perhexiline improves cardiac energetics, left ventricular function, and symptoms of heart failure by altering cardiac substrate utilization." | 5.20 | Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. ( Abozguia, K; Beadle, RM; Bowater, S; Frenneaux, MP; Horowitz, J; Kuehl, M; Leyva, F; Thies, F; Wagenmakers, AJ; Williams, LK; Yousef, Z, 2015) |
| "Heart failure is a major cause of morbidity and mortality in society." | 2.76 | Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial. ( Abozguia, K; Beadle, RM; Frenneaux, MP; Leon, FL; Patel, K; Wagenmakers, A; Williams, LK; Yousef, Z, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cappola, TP | 1 |
| Beadle, RM | 3 |
| Williams, LK | 2 |
| Kuehl, M | 1 |
| Bowater, S | 1 |
| Abozguia, K | 2 |
| Leyva, F | 1 |
| Yousef, Z | 2 |
| Wagenmakers, AJ | 1 |
| Thies, F | 1 |
| Horowitz, J | 1 |
| Frenneaux, MP | 3 |
| Davogustto, G | 1 |
| Taegtmeyer, H | 1 |
| Patel, K | 1 |
| Leon, FL | 1 |
| Wagenmakers, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic Manipulation in Chronic Heart Failure[NCT00841139] | Phase 2 | 50 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for perhexiline and Cardiomyopathy, Congestive
| Article | Year |
|---|---|
Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Cardiovascular Agents; Double-Blind Method; Echocardiography; Energy Metabo | 2015 |
Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial.
Topics: Adenosine Triphosphate; Cardiac Catheterization; Cardiomyopathy, Dilated; Cardiovascular Agents; Dou | 2011 |
3 other studies available for perhexiline and Cardiomyopathy, Congestive
| Article | Year |
|---|---|
Perhexiline: lessons for heart failure therapeutics.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Humans; Male; Myocardium; Perhexi | 2015 |
Perhexiline, Cardiac Energetics, and Heart Failure: Lessons From the First Law of Thermodynamics.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Humans; Male; Myocardium; Perhexi | 2015 |
Reply: Perhexiline, Cardiac Energetics, and Heart Failure: Lessons From the First Law of Thermodynamics.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Humans; Male; Myocardium; Perhexi | 2015 |